Pretorius M, Scholl FG, McFarlane JA, Murphey LJ, Brown NJ. A pilot study indicating that bradykinin B2 re- ceptor antagonism attenuates protamine-related hypoten- sion after cardiopulmonary bypass. Clin Pharmacol Ther 2005;78:477 85. 111. Lee GM, Welsby IJ, Phillips-Bute B, Ortel TL, Arepally GM. High incidence of antibodies to protamine and protamine/ heparin complexes in patients undergoing cardiopulmo- nary bypass. Blood 2013;121:2828 35. 112. Bakchoul T, Zollner H, Amiral J, et al. Anti-protamine- heparin antibodies: incidence, clinical relevance, and path- ogenesis. Blood 2013;121:2821 7. 113. Vincent GM, Janowski M, Menlove R. Protamine allergy reactions during cardiac catheterization and cardiac sur- gery: risk in patients taking protamine-insulin preparations. Cathet Cardiovasc Diagn 1991;23:164 8. 114. Bernabei A, Gikakis N, Maione TE, et al. Reversal of heparin anticoagulation by recombinant platelet factor 4 and prot- amine sulfate in baboons during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1995;109:765 71. 115. Levy JH, Cormack JG, Morales A. Heparin neutralization by recombinant platelet factor 4 and protamine. Anesth Analg 1995;81:35 7. 116. Demma L, Levy JH. A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass. Anesth Analg 2012;115:1273 8. 117. Kikura M, Lee MK, Levy JH. Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after car- diopulmonary bypass. Anesth Analg 1996;83:223 7. 118. Stafford-Smith M, Lefrak EA, Qazi AG, et al. Ef cacy and safety of heparinase I versus protamine in patients under- going coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology 2005;103:229 40. 662 Ann Thorac Surg ANTICOAGULATION DURING CARDIOPULMONARY BYPASS 2018;105:650 62 REPORT